Your AI-Trained Oncology Knowledge Connection!

Ovarian Cancer: Frontline Therapy : Episode 1

Initial Therapy Options for Advanced Ovarian Cancer

April 1, 2021

By Rebecca Previs, MD

Video

Dr. Rebecca Previs reviews first line treatment options for patients with advanced ovarian cancer.

EP: 1.Initial Therapy Options for Advanced Ovarian Cancer

EP: 2.Role of Bevacizumab for Initial Therapy in Advanced Ovarian Cancer

EP: 3.Somatic and Germline Testing in Advanced Ovarian Cancer

EP: 4.Front Line Maintenance Options in Advanced Ovarian Cancer

EP: 5.Selecting a PARP Inhibitor for Front Line Maintenance in Advance Ovarian Cancer

EP: 6.Identifying Patients Appropriate for Front Line Maintenance Therapy in Advanced Ovarian Cancer

EP: 7.Impact of Initial Therapy on Front Line Maintenance Treatment Choice in Advanced Ovarian Cancer

EP: 8.Emerging Front-Line Maintenance Therapies for Advanced Ovarian Cancer

EP: 9.Treatment Considerations for PARP Inhibitors in First-Line Maintenance Therapy in Patients With Advanced Ovarian Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.

Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.

Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.